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INTRODUCTION: Cardiovascular disease is one of the main causes of mortality and morbidity in diabetic patients.
This study evaluated the effects of diabetes on myocardial capillary density and several serum angiogenic factors
including nitric oxide, vascular endothelial growth factor, and soluble vascular endothelial growth factor receptors.
METHODS: Twelve male rats were divided into two groups: control and diabetic (n=6 each). Diabetes was induced
with a single dose of streptozotocin (50 mg/kg). After 21 days, capillary density in the myocardial tissue was
evaluated using immunohistochemical staining and is reported as capillaries per mm
2. Blood samples were collected
before and after the induction of diabetes.
RESULTS: In the diabetic group, serum nitric oxide and soluble vascular endothelial growth factor receptor 2
concentrations were lower than the levels in the control group, while the level of soluble vascular endothelial
growth factor receptor 1 was significantly higher. There was no significant change in the serum vascular endothelial
growth factor concentration between the diabetic and control groups; however, the ratio of vascular endothelial
growth factor to vascular endothelial growth factor receptor 1 was significantly lower in the diabetic animals. The
myocardial capillary density was also lower in the diabetic group compared with the control group (1549¡161 vs.
2156¡202/mm
2, respectively).
CONCLUSION: Reduced serum nitric oxide and vascular endothelial growth factor receptor 2 levels, increased serum
vascular endothelial growth factor receptor 1 levels and a lower vascular endothelial growth factor to vascular
endothelial growth factor receptor 1 ratio may be responsible for the decreased myocardial capillary density in
diabetic rats.
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INTRODUCTION
Cardiovascular disease is one of the main causes of mortality
and morbidity in diabetic subjects, and several long-term
complications of diabetes involve impaired angiogenesis.
Angiogenesis is the growth of new capillaries from pre-existing
vessels
1 and occurs during physiological conditions such as
wound healing. However, abnormal angiogenesis may occur in
some pathological conditions, including diabetic retinopathy.
1
Nitric oxide (NO) and vascular endothelial growth factor
(VEGF) are important factors affecting angiogenesis.
2,3 NO
has important roles in multiple physiological processes and
pathological states,
4,5 and VEGF and its receptors have essen-
tial roles in pathological and physiological angiogenesis.
2,6
The two VEGF receptor subtypes that are primarily
involved in angiogenesis are VEGF receptor type 1
(VEGFR-1) and VEGF receptor type 2 (VEGFR-2). Soluble
VEGFR-1 (sVEGFR-1) binds with a high affinity to VEGF
and reduces VEGF activity and angiogenesis,
6-8 whereas
VEGFR-2 has proangiogenic effect in the angiogenesis
process.
9 Increased VEGF-mediated angiogenesis in dia-
betic retinopathy and nephropathy and a decreased
angiogenic response in wound healing and ulcers have
been documented in diabetic subjects.
10,11
This study aimed to evaluate the effect of diabetes on the
serum concentrations of VEGF, NO and the soluble forms of
VEGFR-1 and VEGFR-2 (sVEGFR-1 and sVEGFR-2) as well
as myocardial capillary density in type I diabetic rats.
METHODS
Animals
Male Wistar rats (aged 10–12 weeks, weighing 230¡30 g)
were used in the present study. The animals were kept two
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1419per cage at room temperature (20–25˚C) with a 12 h light/
dark cycle and ad libitum access to food and water. The
experimental protocols were approved by the ethics
committee of Isfahan University of Medical Sciences.
Induction of Diabetes
After one week of adaptation to the animal room, the rats
were intraperitoneally injected with a single 50 mg/kg dose
of streptozotocin (STZ, Sigma) to induce diabetes.
12,13
STZ was dissolved in cold, normal saline and administered
immediately. Two days after injection, the fasting blood
glucose levels were determined. Animals with blood
glucose greater than 300 mg/dl were considered dia-
betic.
12,13 In the control group, normal saline was injected.
Experimental Design
The rats were divided into normal and diabetic groups
(n=6 each). Blood samples were taken before and after the
induction of diabetes. The samples were centrifuged, and
the serum was kept at -70˚C until the serum VEGF, NO,
sVEGFR-1, and sVEGFR-2 concentrations were measured.
After 21 days, the animals were euthanized. The apex of the
heart was removed, washed with normal saline and fixed in
formalin solution for immunohistochemical evaluation.
Body weight was measured before induction of diabetes
and 21 days after the experiment.
Serum VEGF, sVEGFR-1, sVEGFR-2, and NO
Measurements
Serum VEGF, sVEGFR-1, and sVEGFR-2 concentrations
were measured using the quantitative sandwich enzyme
immunoassay technique with the appropriate kits (R&D
Systems, Minneapolis, USA).
14,15 The serum nitrite concen-
tration, one of the main metabolites of NO, was determined
using the Griess reagent method (Promega, Madison,
USA).
16
Immunohistochemistry
Capillary density was measured using immunohistochem-
istry with a rat monoclonal antibody directed against mouse
CD31 (Abcam, Cambridge UK).
17 Fifteen fields of three
different sections from each cardiac tissue sample were
randomly examined using a light microscope (4006)b yt w o
blinded observers. The number of capillaries in each tissue
sample is reported as the number of capillaries per mm
2.
Statistical Analysis
All values are reported as the mean ¡ SE. Student’s t-test
was used to evaluate differences between the two groups.
Paired data were used for the data analysis before and after
Figure 1 - Serum nitrite concentration in control and diabetic rats before and after the induction of diabetes. *p,0.05.
Table 1 - Fasting blood glucose level (mg/dl) and body
weight (g) before and after the induction of diabetes.
Group n Body Weight (g)
Fasting Blood Glucose Level
(mg/dl)
Day 0 Day 21 Day 0 Day 21
control 6 245¡4.8 285.71¡7.4* 122.57¡3.5 117.43¡5.4
diabetic 6 240¡7.6 173¡9.6* 125¡6.0 508.6¡25.4*
*p,0.05 versus day 0.
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1420the induction of diabetes. Bivariate correlations were
calculated using Pearson’s correlation coefficient. A p-value
less than 0.05 was considered statistically significant.
RESULTS
Blood glucose and body weight
Table 1 shows the fasting blood glucose levels and body
weight in the two groups. Body weight significantly
increased over the course of the experiment in the control
group, whereas the body weight of diabetic rats decreased
over time (p,0.05). The fasting blood glucose level in the
diabetic animals was higher than the level in the controls
and remained elevated throughout the experiment.
Effects of diabetes on serum angiogenic factors
Figure 1 illustrates the serum NO concentration in the two
groups before and after the induction of diabetes. In the
diabetic group, the serum NO level was significantly
decreased at the end of experiment when compared with
the level prior to the induction of diabetes (p,0.05; Figure 1).
While there was no significant difference in the serum VEGF
concentration between the groups (Figure 2A), the serum
sVEGFR-1 concentration was increased and the sVEGFR-2
level was decreased in the diabetic group compared with
the control group (p,0.05; Figure 2B and C). In addition, the
VEGF:sVEGFR-1 ratio in diabetic animals was lower than
the ratio in the controls (p,0.05; Figure 2D).
Effect of diabetes on myocardial capillary density
The capillary density in the myocardial tissue (expressed
as the number of capillaries per mm
2) was significantly
reduced in the diabetic group compared with the control
group (p,0.05) (Figure 3B). Representative images of the
immunohistochemical staining are presented in figure 3A.
Correlation analysis
In the correlation analysis, we found that capillary density
in myocardial tissue was positively correlated with the
serum nitrite level (r=0.70), the VEGF level (r=0.40), the
sVEGFR-1 level (r=-0.69) and the VEGF:sVEGFR-1 ratio
(r=0.71) (Figure 4).
DISCUSSION
Our results show that the capillary density in myocardial
tissue, the serum NO level, and the sVEGFR-2 level in
diabetic rats were lower than the levels in the controls, while
the sVEGFR-1 level was higher in the diabetic animals.
Moreover, the VEGF:sVEGFR-1 ratio was significantly
decreased in diabetic animals. The correlation analysis
demonstrated that capillary density in myocardial tissue
was correlated with the above serum angiogenic markers.
Angiogenesis is controlled by a number of proangiogenic
and antiangiogenic factors that are released in tissues. NO
and VEGF have crucial roles during angiogesis.
6,18 NO not
only has a direct effect on angiogenesis, but other
Figure 2 - The serum VEGF (A), sVEGF-R1 (B), and sVEGF-R2 concentrations (C) and the VEGF:VEGF-R1 ratio (D) before (white column)
and after (black column) the induction of diabetes. *p,0.05 compared to day 0.
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1421angiogenic growth factors affect angiogenesis as well by
increasing NO production.
19 A decrease in NO production
in endothelial NO synthase–deficient mice disrupts the
development of the coronary vessels and angiogenesis.
20 In
the present study, the serum NO concentration in diabetic
rats was lower than the concentration in the control group,
which supports the results of previous studies.
21-24 Some
possible mechanisms responsible for decreased NO produc-
tion under high glucose conditions include the suppression
of endothelial NO synthase expression and activity,
25
overproduction of superoxides,
26 and activation of protein
kinase C.
23
VEGF has been shown to be an important inducer of
angiogenesis in a variety of in vivo models.
6 Several
experimental and clinical reports examining the effect of
diabetes on the serum or plasma VEGF level have been
published, and the results are contradictory: an increase,
27-29
decrease,
30,31 and no change
32,33 in the VEGF levels in type I
and II diabetes have been reported. In the present study,
although the capillary density was lower in diabetic
animals, the serum VEGF concentration was similar to that
in control animals. It has been suggested that even with an
increase or no change in the VEGF level, the VEGF signaling
pathway is defective during diabetes, and diabetes
is considered VEGF resistant.
29,34 In a recent study,
Hazarika et al. showed that in the absence of ischemia,
VEGF signaling in diabetic mice was lower than that in
control mice.
35 They also showed that in the absence of
ischemia, diabetic mice had increased VEGF and sVEGFR-1
levels and decreased phospho-AKT/AKT and phospho-
endothelial NO synthase/endothelial NO synthase levels.
Lu et al. also found that the post-ischemic capillary density
and revascularization in the limbs of diabetic rats was
decreased, with reduced mRNA and protein expression of
eNOS, VEGF, and bFGF.
31 However, despite the similarity
in serum VEGF levels between the groups, we found that
diabetic animals had higher sVEGFR-1 and lower sVEGFR-2
levels compared with the controls. sVEGFR-1 binds with a
high affinity to VEGF
9 and reduces VEGF activity, endothe-
lial cell proliferation, angiogenesis and tumor growth.
6-8
Thus, sVEGFR-1 acts as an antagonist of VEGF.
36 In
contrast, VEGF-R2 is an effector of proangiogenic signaling
in the angiogenesis process.
9 Therefore, reduced sVEGFR-2
levels and increased sVEGFR-1 levels in the serum may be
responsible for the lower capillary density in the myocardial
tissue of diabetic rats. We also investigated the VEGF to
sVEGFR-1 ratio, as some studies have used the
VEGF:sVEGFR-1 ratio as an indicator of angiogenesis
status.
37,38 In the present study, we found that the
VEGF:sVEGFR-1 ratio was reduced in diabetic rats, which
suggests decreased angiogenesis in the diabetic group.
In conclusion, myocardial capillary density was lower in the
diabeticgroupcomparedwiththecontrolgroup.Furthermore,
the lower serum levels of the proangiogenic factors NO and
sVEGFR-2, the higher level of the antiangiogenic factor
sVEGFR-1 and the reduced VEGF:sVEGFR-1 ratio may
Figure 3 - Effect of diabetes on the myocardial capillary density. A. Representative images of the immunohistochemical staining (4006)
with an anti-CD31 monoclonal antibody. B. Myocardial capillary density in the control and diabetic groups. n=6 per group. * p,0.05.
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1422Figure 4 - Correlation between the capillary density in myocardial tissue and the serum nitrite (r=0.70) (A), sVEGFR-1 (r=-0.69) (B), and
VEGF (r=0.40) (C) levels.
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1423explain the reduced coronary angiogenesis observed in
diabetic animals.
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